Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
11°
Clear
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Capricor Therap
(NQ:
CAPR
)
18.62
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Capricor Therap
< Previous
1
2
3
4
Next >
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
September 17, 2024
Capricor Therapeutics partners with Nippon Shinyaku for the European commercialization of Duchenne muscular dystrophy treatment, deramiocel, with a potential $1.5 billion in milestone payments from...
Via
Benzinga
Unveiling 6 Analyst Insights On Capricor Therapeutics
July 02, 2024
Via
Benzinga
What's Going On With Capricor Therapeutics Stock Friday?
June 28, 2024
The biotechnology company said deramiocel increased cardiac function based on several different measures.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
June 11, 2024
Via
Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
June 11, 2024
Capricor Therapeutics announced successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA).
Via
Benzinga
What's Going On With Capricor Therapeutics Stock Tuesday?
June 04, 2024
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is trading higher Tuesday after the company announced three-year results from the ongoing HOPE-2 open-label extension
Via
Benzinga
Expert Ratings For Capricor Therapeutics
May 14, 2024
Via
Benzinga
Recap: Capricor Therapeutics Q4 Earnings
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
CAPR Stock Earnings: Capricor Therapeutics Misses EPS, Misses Revenue for Q1 2024
May 13, 2024
CAPR stock results show that Capricor Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Capricor Therapeutics's Earnings Outlook
February 28, 2024
Via
Benzinga
Preview: Capricor Therapeutics's Earnings
November 13, 2023
Via
Benzinga
FlexShopper And 3 Other Penny Stocks Insiders Are Buying
October 12, 2023
The Dow Jones closed higher by around 65 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cadrenal Therapeutics And 3 Other Stocks Under $3 Insiders Are Buying
October 09, 2023
The Dow Jones closed higher by around 290 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
US Stocks Turn Lower; Dow Tumbles Over 200 Points
September 29, 2023
U.S. stocks turned lower toward the end of trading, with the Dow Jones falling over 200 points on Friday. The Dow traded down 0.70% to 33,432.17 while the NASDAQ fell 0.15% to 13,181.22. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Recap: Capricor Therapeutics Q1 Earnings
May 11, 2023
Via
Benzinga
Earnings Preview For Capricor Therapeutics
March 14, 2023
Via
Benzinga
Why SeaStar Medical Holding Shares Are Trading Higher By Around 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
September 29, 2023
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group for $13 per share.
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 29, 2023
Via
Benzinga
Crude Oil Down 1% Following PCE Data; Blue Apron Shares Surge
September 29, 2023
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday. The Dow traded up 0.13% to 33,710.74 while the NASDAQ rose 0.99% to 13,331.54. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Nasdaq Gains Over 1%; Nike Posts Upbeat Earnings
September 29, 2023
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 1% on Friday. The Dow traded up 0.24% to 33,746.70 while the NASDAQ rose 1.22% to 13,362.51. The S&P 500 also rose,...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
12 Health Care Stocks Moving In Friday's Pre-Market Session
September 29, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
August 29, 2023
Via
Benzinga
Top 5 Health Care Stocks That May Fall Off A Cliff
August 23, 2023
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.
Via
Benzinga
Capricor Highlights Preclinical Data From Its Closed COVID-19 Vaccine Study
January 12, 2023
Via
Benzinga
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022
October 26, 2022
Upgrades
Via
Benzinga
Recap of Tuesday's Biotech Catalysts - End Of The Day Summary
July 19, 2022
The U.S. Food and Drug Administration (FDA) has granted tentative approval to Avadel Pharmaceuticals’ (NASDAQ: AVDL) lead candidate LUMRYZ (FT218) for the treatment of excessive daytime sleepiness...
Via
Benzinga
Capricor Initiates Late-Stage Neuropsychiatric Disorder Study
July 19, 2022
Capricor Therapeutics (NASDAQ: CAPR) initiated dosing of first patient in HOPE-3, a Phase 3 clinical trial investigating CAP-1002 for treating late-stage Duchenne muscular dystrophy (DMD).
Via
Benzinga
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying
July 08, 2022
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.